chlorprothixene Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
623 113-59-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorprothixene
  • chlorprothixen
  • chlorprotixen
  • chlorprotixene
  • chlothixen
  • chorprothixene
  • chlorprothixene hydrochloride
  • chlorprothixene HCl
  • taractan
A thioxanthine with effects similar to the phenothiazine antipsychotics.
  • Molecular weight: 315.86
  • Formula: C18H18ClNS
  • CLOGP: 5.48
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -5.94
  • ROTB: 3

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
50 mg P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 41 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 25.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 19, 1967 FDA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 87.38 47.90 21 53 32733 2325278
Suicide attempt 49.50 47.90 11 63 11271 2346740

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC N05AF03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Thioxanthene derivatives
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:48873 cholinergic antagonist
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:65190 first generation antipsychotic
MeSH PA D015259 Dopamine Agents
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Shock contraindication 27942005
Parkinsonism contraindication 32798002
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Alcohol withdrawal syndrome contraindication 191480000
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Breastfeeding (mother) contraindication 413712001
Carcinoma of female breast contraindication 447782002
Drug Induced CNS Depression contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.66 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.53 CHEMBL CHEMBL
D(4) dopamine receptor GPCR Ki 9.19 PDSP
Solute carrier family 22 member 1 Transporter IC50 4.11 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 8.52 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.74 CHEMBL
Histamine H1 receptor GPCR Ki 8.43 CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.34 CHEMBL
D(1B) dopamine receptor GPCR Ki 8.05 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 7.96 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 7.74 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 7.66 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 7.60 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 9.37 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 7.55 PDSP
5-hydroxytryptamine receptor 7 GPCR Ki 8.25 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.29 CHEMBL
Histamine H1 receptor GPCR IC50 8.97 CHEMBL

External reference:

IDSource
D002749 MESH_DESCRIPTOR_UI
4017788 VUID
N0000146149 NUI
C0008290 UMLSCUI
D00790 KEGG_DRUG
268KCR965N UNII
6469-93-8 SECONDARY_CAS_RN
57002000 SNOMEDCT_US
4017788 VANDF
001516 NDDF
2406 RXNORM
387317000 SNOMEDCT_US
886 INN_ID
CHEMBL908 ChEMBL_ID
DB01239 DRUGBANK_ID
CHEBI:3651 CHEBI
667467 PUBCHEM_CID
CHEMBL1256658 ChEMBL_ID

Pharmaceutical products:

None